Oculis Holding AG is a clinical-stage biopharmaceutical company dedicated to saving sight and improving eye care through innovative non-invasive treatments. The company's lead product candidate, OCS-01, utilizes its proprietary OPTIREACH formulation technology to deliver dexamethasone via topical eye drops for the treatment of diabetic macular edema, and is currently in Phase 3 clinical trials. Its pipeline also includes OCS-02 (Licaminlimab), a topical biologic candidate for dry eye disease, and OCS-05 (Privosegtor), a neuroprotective agent targeting acute optic neuritis and glaucoma. Headquartered in Zug, Switzerland, Oculis operates internationally with an additional presence in the United States and Iceland. The company transitioned to the public markets in March 2023 following a business combination with the special purpose acquisition company European Biotech Acquisition Corp.
